A Pilot Study Protocol for a Personalized Treatment Platform in Infants, Children, and Young Adults 0-45 Years with Newly Diagnosed Acute Lymphoblastic Leukaemia
Led by Mats Heyman · Updated on 2026-08-13
500
Participants Needed
57
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a comprehensive treatment approach for infants, children, and young adults aged 0 to 45 years with newly diagnosed acute lymphoblastic leukaemia ALL. This pilot study gathers experiences from multiple renowned study groups to establish a unified platform protocol that supports personalized risk-based diagnosis and treatment. The study aims to optimize survival and quality of life, addressing both under-treatment and over-treatment risks in this patient group.
The study is observational and does not involve specific experimental interventions but uses standard of care treatments defined by the master protocol. It incorporates a personalized algorithm based on clinical and genetic factors to guide treatment decisions. High-risk patients may be considered for advanced therapies such as Chimeric Antigen Receptor T-cell CAR-T therapy as alternatives to more intensive treatments. The study also supports translational and therapy-related research within this platform.
Participants are observed under routine care at participating pediatric oncology or adult hematology centers. Data collection includes diagnosis confirmation, treatment response, and survival outcomes over a 5-year period. Researchers monitor event-free survival and overall survival compared to historical controls, aiming to improve long-term results. The study runs until June 2033, with ongoing data registration, collaboration optimization, and quality checks to support future randomized trials.
CONDITIONS
Brief Title
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Research Team
T
Trial Central Office
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Nordic Society for Pediatric Hematology and Oncology
Collaborating Sponsor
Who Can Participate
Age: 0Years - 45Years
All Genders
Eligibility Criteria
You may qualify if you...
Patients newly diagnosed with T-cell or B-cell precursor acute lymphoblastic leukaemia (ALL) confirmed by an accredited laboratory
Age from 0 up to just before 46 years at diagnosis
Patients with surface immunoglobulin negative BCP-ALL with IG::MYC rearrangement unless concurrent BCL2/6 rearrangement
Signed informed consent according to country-specific age guidelines
Diagnosis and treatment at a participating pediatric oncology or adult hematology center
Permanent residence or intention to settle in a participating country
All women of childbearing potential must have a negative pregnancy test within 2 weeks before treatment start
You will not qualify if you...
Age under 365 days with KMT2A-rearranged BCP-ALL
Age above 45 years at diagnosis
Previous malignant diagnosis or relapse of ALL
Patients with mature B-ALL or concurrent IG::MYC and BCL2/6 rearrangement
Patients with Ph-positive ALL
Known ALL prone syndromes except Down syndrome
Treatment with systemic corticosteroids over 10 mg/m2/day for more than one week or chemotherapy in 4 weeks before diagnosis
Contraindications preventing adequate treatment according to protocol
Conditions interfering with study participation or compliance
Women pregnant at diagnosis or breastfeeding
Women of childbearing potential and fertile men unwilling to use effective contraception during therapy
Missing essential registration data at diagnosis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Observation and Data Collection
Duration - Up to 14 years
Participants receive standard of care treatment while their diagnosis, treatment response, and survival data are collected. This involves routine clinical care at participating centers without additional experimental interventions.
Regular clinical visits as part of usual care
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
A Pilot Study Protocol for a Personalized Treatment Platform in Infants, Children, and Young Adults 0-45 Years with Newly Diagnosed Acute Lymphoblastic Leukaemia
ALLTogether1 Treatment Study for Patients Aged 0 to 45 With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase III Study of Anti-CD19 CAR T-Cell Therapy with Rituximab and Chemotherapy for Advanced B-Cell Leukemias
Study of Locally Made CD19 CAR-T Cell Therapy for Relapsed or Resistant Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma in Patients Aged 3 to 70 Years
Study of Fish Oil to Reduce High Blood Fat Levels and Side Effects in Children and Young Adults With Acute Lymphoblastic Leukemia
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Veerle Mondelaers, Stefan Suciu, Barbara De Moerloose...
Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
Rob Pieters, Hester de Groot-Kruseman, Vincent Van der Velden...